Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide + Rituximab in B-cell Lymphoma
NCT00288067Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenretinide in B cell lymphoma, chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Dose-limiting Toxicity and Response Rate up to 7 years. Started Oct 2005; status: terminated.
02
Drugs
fenretinide
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00288067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00288067.